Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022.

Michael J Morris, Oliver Sartor, Johann S de Bono, Karim Fizazi, Scott T Tagawa

Abstract readEditorialComment

In one paragraph

Article in European urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit.BJC reports · 2024
Review
Relationship among Parkinson's disease, constipation, microbes, and microbiological therapy.World journal of gastroenterology · 2024
Review

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Michael J MorrisMemorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: morrism@mskcc.org.

Oliver SartorSchool of Medicine, Tulane University, New Orleans, LA, USA.

Johann S de BonoInstitute of Cancer Research and Royal Marsden Hospital, London, UK.

Karim FizaziGustave Roussy Institute, Paris-Saclay University, Villejuif, France.

Scott T TagawaWeill Cornell Medicine, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstate-Specific AntigenRadioisotopesDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617Radioisotopes

Identifiers

PMID37032186

DOI10.1016/j.eururo.2023.03.028

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.